Superluminal Medicines is a generative biology and chemistry company developing a differentiated pipeline and revolutionizing the speed and accuracy of how medicine is created. The company’s platform creates candidate-ready compounds with unprecedented speed using a comprehensive combination of deep biology and chemistry expertise, machine learning, and proprietary big data infrastructure.
Generative Biology, Human Ingenuity, Faster Breakthroughs
ACCELERATING NEW POSSIBILITIES IN DRUG DISCOVERY AND DEVELOPMENT
News
September 30, 2024 Superluminal Medicines Announces Formation of Scientific Advisory Board
September 9, 2024 Superluminal Medicines Closes $120 Million Series A Round
Careers
Join us to accelerate new possibilities in drug discovery.
» View our open jobs
Our Team
Cony D'Cruz
Co-founder & CEO
Publications
Are Deep Learning Structural Models Sufficiently Accurate for Free-Energy Calculations? Application of FEP+ to AlphaFold2-Predicted Structures » FULL ARTICLE
Are Deep Learning Structural Models Sufficiently Accurate for Virtual Screening? Application of Docking Algorithms to AlphaFold2 Predicted Structures » FULL ARTICLE
Optimizing Drug Design by Merging Generative AI With Active Learning Frameworks » FULL ARTICLE
Superluminal Medicines, Inc.
15 Necco St.
Lilly Gateway Labs, 4th Floor
Boston, MA 02210
(781) SUN - 8484
15 Necco St.
Lilly Gateway Labs, 4th Floor
Boston, MA 02210
(781) SUN - 8484